Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris

IJC Metabolic and Endocrine

Volumn 4, Issue , 2014, Pages 47-52

  Nozue, Tsuyoshi ^a   Yamagishi, Sho ichi ^b   Takeuchi, Masayoshi ^c   Hirano, Tsutomu ^d   Yamamoto, Shingo ^e   Tohyama, Shinichi ^f   Fukui, Kazuki ^g   Umezawa, Shigeo ^h   Onishi, Yuko ^h   Kunishima, Tomoyuki ⁱ   Hibi, Kiyoshi ^j   Terashima, Mitsuyasu ^k   Michishita, Ichiro ^a  

^a Yokohama Sakae Kyosai Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Tsurumi Nishiguchi Hospital   (Japan)

^f Yokohama Seamen's Insurance Hospital   (Japan)

^g Kanagawa Prefectural Cardiovascular and Respiratory Diseases Center Hospital   (Japan)

^h Hiratsuka Kyosai Hospital   (Japan)

ⁱ TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^k Cardiovascular Imaging Center   (Japan)

more..

Author keywords

Advanced glycation end products; Plaque; Receptor for advanced glycation end products; Statin; Virtual histology intravascular ultrasound

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION AND FOLLOW UP; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; REGRESSION ANALYSIS; RISK FACTOR;

EID: 84908052646     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2014.07.002     Document Type: Article

References (40)

1. Schmidt A.M., Stern D. Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep 2000, 5:430-436.
2. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84:489-497.
3. Yamagishi S., Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005, 11:2279-2299.
4. Yamagishi S., Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed) 2010, 2:1184-1195.
5. Park L., Raman K.G., Lee K.J., Lu Y., Ferran L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998, 4:1025-1031.
6. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 2002, 106:2827-2835.
7. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 2007, 13:185-189.
8. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., et al. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 2008, 22:3716-3727.
9. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.
10. Nin J.W., Jorsal A., Ferreira I., Schalkwijk C.G., Prins M.H., Parving H.H., et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010, 59:2027-2032.
11. Colhoun H.M., Betteridge D.J., Durrington P., Hitman G., Neil A., Livingstone S., et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011, 60:2379-2385.
12. Fujisawa K., Katakami N., Kaneto H., Naka T., Takahara M., Sakamoto F., et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013, 227:425-428.
13. Nicholls S.J., Hsu A., Wolski K., Hu B., Bayturan O., Lavoie A., et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol 2010, 55:2399-2407.
14. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.
15. Quade-Lyssy P., Kanarek A.M., Baiersdörfer M., Postina R., Kojro E. Statins stimulate the production of a soluble form of the receptor for advanced glycation end products. J Lipid Res 2013, 54:3052-3061.
16. Tam H.L., Shiu S.W., Wong Y., Chow W.S., Betteridge D.J., Tan K.C. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. Atherosclerosis 2010, 209:173-177.
17. Nozue T., Yamamoto S., Tohyama S., Umezawa S., Kunishima T., Sato A., et al. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis. Am Heart J 2012, 163:191-199.
18. Mintz G.S., Nissen S.E., Anderson W.D., Bailey S.R., Erbel R., Fitzgerald P.J., et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001, 37:1478-1492.
19. Nair A., Kuban B.D., Tuzcu E.M., Schoenhagen P., Nissen S.E., Vince D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106:2200-2206.
20. Ito Y., Fujimura M., Ohta M., Hirano T. Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem 2011, 57:57-65.
21. Takeuchi M., Makita Z., Bucala R., Suzuki T., Koike T., Kameda Y. Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo. Mol Med 2000, 6:114-125.
22. Nakamura K., Yamagishi S., Adachi H., Kurita-Nakamura Y., Matsui T., Yoshida T., et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 2007, 23:368-371.
23. Selvin E., Halushka M.K., Rawlings A.M., Hoogeveen R.C., Ballantyne C.M., Coresh J., et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013, 62:2116-2121.
24. Yamagishi S., Imaizumi T. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) may reflect tissue RAGE expression in diabetes. Arterioscler Thromb Vasc Biol 2007, 27:e32.
25. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005, 16:2363-2372.
26. Nakamura K., Yamagishi S., Nakamura Y., Takenaka K., Matsui T., Jinnouchi Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 2005, 70:137-141.
27. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 2007, 43:1255-1262.
28. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 2003, 108:1070-1077.
29. Calkin A.C., Giunti S., Sheehy K.J., Chew C., Boolell V., Rajaram Y.S., et al. The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation. Diabetologia 2008, 51:1731-1740.
30. Cuccurullo C., Iezzi A., Fazia M.L., De Cesare D., Di Francesco A., Muraro R., et al. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol 2006, 26:2716-2723.
31. Cipollone F., Fazia M., Iezzi A., Zucchelli M., Pini B., De Cesare D., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 2003, 107:1479-1485.
32. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
33. Ogita M., Miyauchi K., Morimoto T., Daida H., Kimura T., Hiro T., et al. Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome-subanalysis of the JAPAN-ACS study. Atherosclerosis 2013, 226:275-280.
34. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
35. Jinnouchi Y., Yamagishi S., Takeuchi M., Ishida S., Jinnouchi Y., Jinnouchi J., et al. Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin Exp Med 2006, 6:191-193.
36. Soro-Paavonen A., Watson A.M., Li J., Paavonen K., Koitka A., Calkin A.C., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008, 57:2461-2469.
37. Ueno H., Koyama H., Shoji T., Monden M., Fukumoto S., Tanaka S., et al. Receptor for advanced glycation end-products (RAGE) regulation of adiposity and adiponectin is associated with atherogenesis in apoE-deficient mouse. Atherosclerosis 2010, 211:431-436.
38. Kimura Y., Hyogo H., Yamagishi S., Takeuchi M., Ishitobi T., Nabeshima Y., et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010, 45:750-757.
39. Nakamura T., Sato E., Fujiwara N., Kawagoe Y., Takeuchi M., Maeda S., et al. Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid Med Cell Longev 2010, 3:304-307.
40. Fukami A., Adachi H., Yamagishi S., Matsui T., Ueda S., Nakamura K., et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population. Metabolism 2009, 58:1688-1693.